| pubmed-article:12810046 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12810046 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:12810046 | lifeskim:mentions | umls-concept:C0023290 | lld:lifeskim |
| pubmed-article:12810046 | lifeskim:mentions | umls-concept:C0021853 | lld:lifeskim |
| pubmed-article:12810046 | lifeskim:mentions | umls-concept:C0442027 | lld:lifeskim |
| pubmed-article:12810046 | lifeskim:mentions | umls-concept:C1753353 | lld:lifeskim |
| pubmed-article:12810046 | lifeskim:mentions | umls-concept:C0547047 | lld:lifeskim |
| pubmed-article:12810046 | pubmed:issue | 1-2 | lld:pubmed |
| pubmed-article:12810046 | pubmed:dateCreated | 2003-6-17 | lld:pubmed |
| pubmed-article:12810046 | pubmed:abstractText | Drugs currently available for visceral leishmaniasis treatment are potentially toxic, have to be administered by parenteral route and frequently give rise to drug resistance, due to the involvement of P-glycoproteins (P-gp) in Leishmania. The purpose of this study was to investigate a possible inhibitory effect of 2n-propylquinoline (2nPQ) on P-gp activity. 2nPQ is a new oral anti-leishmanial drug that has demonstrated its efficacy in BALB/c infected mice with Leishmania donovani [Antimicrob. Agents Chemother. 37 (1993) 859]. Rat everted gut sacs and human intestinal Caco-2 cell lines were used to study the effect of 2nPQ on P-gp activity. Our results demonstrate an inhibitory effect of 2nPQ on the P-gp activity with two P-gp substrates (rhodamine 123 and digoxin), two P-gp inhibitors (cyclosporin A and verapamil), and in two different species. Alone or associated with other active drugs, 2nPQ would be very useful to control Leishmania Multi-Drug-Resistance and intestinal P-gp in humans with kala-azar. | lld:pubmed |
| pubmed-article:12810046 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12810046 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12810046 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12810046 | pubmed:issn | 0014-4894 | lld:pubmed |
| pubmed-article:12810046 | pubmed:author | pubmed-author:LacourBB | lld:pubmed |
| pubmed-article:12810046 | pubmed:author | pubmed-author:FarinottiRR | lld:pubmed |
| pubmed-article:12810046 | pubmed:author | pubmed-author:LeroyCC | lld:pubmed |
| pubmed-article:12810046 | pubmed:author | pubmed-author:BanideHH | lld:pubmed |
| pubmed-article:12810046 | pubmed:author | pubmed-author:BelliardA MAM | lld:pubmed |
| pubmed-article:12810046 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12810046 | pubmed:volume | 103 | lld:pubmed |
| pubmed-article:12810046 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12810046 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12810046 | pubmed:pagination | 51-6 | lld:pubmed |
| pubmed-article:12810046 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:meshHeading | pubmed-meshheading:12810046... | lld:pubmed |
| pubmed-article:12810046 | pubmed:articleTitle | Decrease of intestinal P-glycoprotein activity by 2n-propylquinoline, a new oral treatment for visceral leishmaniasis. | lld:pubmed |
| pubmed-article:12810046 | pubmed:affiliation | Laboratoire de Pharmacie Clinique-Physiologie, UPRES 2706, Faculté de Pharmacie, 92296, Châtenay-Malabry Cedex, France. | lld:pubmed |
| pubmed-article:12810046 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12810046 | pubmed:publicationType | In Vitro | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12810046 | lld:pubmed |
